Krystal Biotech Inc KRYS

$322.28 -3.03 (-0.93%)

Valuation

Market cap
9,628,851,000
Revenue TTM
$389,130,000
Net income TTM
$204,830,000
PE ratio
41.67
Forward PE
44.47
Profit margin
52.64%
Debt to equity
0.00

Trading

Volume
425,600
Avg volume
295,158
Day's range
$320.29 – $329.22
Shares out
29,599,000
Stochastic %K
6%
Beta
0.50
Analysts
Strong Sell
Price target
$389.10

Price

Company profile

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bu...

Show more

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Phone
412 586 5830
Website
https://www.krystalbio.com
Address
2100 Wharton Street, Suite 701, Pittsburgh, United States

Latest news

Stocktwits

WAJeff Sep 30, 8:26 PM
$KRYS Sold 5/13 317.66s at 334.50. Really should have sold this at 375 but I got greedy hoping for a 4-tap
0 replies
Quantumup Sep 25, 12:35 PM
H.C. Wainwright reiterated $ABEO Buy-$20 and said: FAYUVI approval slated to yield potentially sizable rewards in the form of royalties and commercial milestone payments. $RARE $KRYS Here's what else H.C. Wainwright had to say: https://x.com/Quantumup1/status/2103463070282432562?s=20
1 replies
Quantumup Sep 18, 3:12 PM
Cantor⬆️ $ABEO's PT to $30 and reiterated at Overweight after Abeona's partner Ultragenyx announced the approval of FAYUVI (UX111, AAV9-based gene therapy) for Sanfilippo syndrome Type A (MPS IIIA). $RARE $KRYS Cantor said in its note: As part of this agreement, Ultragenyx assumed responsibility across development, manufacturing and commercialization, with ABEO eligible for tiered royalties of up to 10% on net sales and commercial milestone payments up to $30M. Following this news, we are raising our PT to $30 from $28 prior.
0 replies
Quantumup Sep 17, 10:33 AM
Roth • MKM🏁 $ABEO and said -- We initiate coverage of ABEO with a Buy rating and 12-month PT of $17. $KRYS Here's what Roth • MKM went on to say in its initiation report: https://x.com/Quantumup1/status/2100533327375556890?s=20
1 replies
piptic Aug 26, 5:19 PM
$KRYS Breaking out
0 replies
JFDI Aug 25, 1:57 PM
$KRYS punched thru
0 replies
Bordeaux17 Aug 21, 6:08 PM
$KRYS A few years ago I started doing work for this company. I wasn’t even interested in biotech at the time. The facility itself caught my attention. One of the cleanest, most meticulous operations I’ve ever stepped foot in.The more I learned about the company, its people, and what they’re building, the more I dug in. Buying the stock ended up being one of my best investment decisions. Still exceeding my expectations. And I’m not done accumulating
0 replies
wizeinvesting Aug 20, 8:30 AM
$KRYS $SCHD A $40,000 purchase can feel like a simple decision: get something you want today or keep the money invested for the future. But beneath that choice is a much bigger question about time, compounding, and financial freedom. For a busy person building wealth, the real cost of a major purchase isn't always the amount leaving your bank account. It's what that money could have become if you had left it working for you for another 10, 20, or 30 years. What if a $40,000 decision today could eventually become hundreds of thousands of dollars—or potentially more—over decades? https://www.wizeinvesting.com/p/krys-s-523-climb-what-consistent-500-investing-could-build
0 replies